Metabolic Diseases: Type 2 Diabetes

Over the past decades the incidence of diabetes has progressively increased. According to the American Diabetes Association (ADA), diabetes affects more than 20 million people in the USA alone. Diabetes is associated with increased risk of a number of serious complications.

Prous Institute's research efforts are focused on developing novel, more effective and safer therapies for type 2 diabetes. One series of compounds was prepared as potent SGLT2 inhibitors. Three series of compounds are being developed as GPR119 agonists. Both classes of compounds work in a completely different way to any of the existing type 2 diabetes therapeutics. Representative compounds for each series include:

 Compound      
 Target / Action  Status
 JRP 206 GPR 119 / Agonist         
Preclinical, Patent application scheduled March 2012
 JRP 227 GPR 119 / Agonist Preclinical, Patent application scheduled January 2012
 JRP 493 SGLT2  / Inhibitor Preclinical, Patent application submitted
 

Type 2 diabetes is characterized as a proinflammatory and procoagulant condition. The high incidence of cardiovascular ischemic events in patients with type 2 diabetes is explained by the development of atherothrombotic lesions. Compounds JRP 206 and JRP 227 have been proven to control glycemia and to have moderate platelet antiaggregatory activity.